The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Mylan lnstitutional Inc. (a Viatris company) is conducting a recall at the retail level of five batches of Esomeprazole Magnesium Delayed-Release Ca psu les, USP 20 mg and four batches of Esomeprazole Magnesium DR Capsules, USP 40 mg, manufactured by Mylan Laboratories Limited and repackaged by Mylan Institutional Inc. in unit dose blisters (UD60). These batches are being recalled due to related compound results obtained during routine stability testing that were found out of specification.

These batches were distributed in the US between January 2021 and March 2022. To date, no reports of adverse reactions associated with these batches have been received.

NDC#	**Material Description / Strength**	**Size**	**MII Batch#**	**MII Exp. Date**
42292-009-16	Esomeprazole Mg DR 20 mg Capsules, USP	UD60	3110438	7/31 /2022
42292-009-16	Esomeprazole Mg DR 20 mg Capsules, USP	UD60	3112743	4/30/2023
42292-009-16	Esomeprazole Mg DR 20 mg Capsules, USP	UD60	3112582	3/3 l /2023
42292-009-16	Esomeprazole Mg DR 20 mg Capsules, USP	UD60	3111708	7/31 / 2022
42292-009-16	Esomeprazole Mg DR 20 mg Capsules, USP	UD60	3111120	7/31/2022
42292-010-16	Esomeprazole Mg DR 40 mg Capsules, USP	UD60	3110437	7/31/20 22

NDC#	Material Description / Strength	Size	MII Batch#	MII Exp. Date
42292-010-16	Esomeprazole Mg DR 40 mg Capsules, USP	UD60	3112173	11/30/2022
42292-010-16	Esomeprazole Mg DR 40 mg Capsules, USP	UD60	3111409	7/31/2022
42292-010-16	Esomeprazole Mg DR 40 mg Capsules, USP	UD60	3110785	7/31/2022